Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Novel small-molecule leads targeting the V2 vasopressin receptor

Oct. 11, 2002

Reduction of RCN incidence with fenoldopam mesilate after contrast angiography

Oct. 10, 2002

Keryx extends manufacturing and negotiating rights for KRX-101

Oct. 8, 2002

Positive clinical results for PT-141 in moderate to severe MED

Oct. 4, 2002

GPI-1485 shows neuroprotective activity in preclinical models of postprostatectomy ED

Oct. 1, 2002

Vardenafil: phase III clinical data discussed at congress, trade name selected

Sep. 27, 2002

Trospium meets endpoints in phase III overactive bladder trial

Sep. 25, 2002

Cozaar reduces the risk of ESRD in patients with type 2 diabetes, nephropathy and hypertension

Sep. 23, 2002

New option available for patients with hypertension and diabetic kidney disease

Sep. 20, 2002

Resiniferatoxin: safe and effective for neurogenic and idiopathic bladder overactivity

Sep. 19, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...